Phreesia Inc. (NYSE:PHR) is one of the stocks that will double in 2026. On December 10, Baird lowered the firm’s price target on Phreesia to $25 from $31 with an Outperform rating on the shares. This announcement was made after the firm updated its model to reflect the company’s latest guidance for 2026-2027. Just a day prior, Phreesia released its FQ3 2026 earnings report, where the company announced a total revenue of $120.3 million, which marked a 13% increase year-over-year. Furthermore, Phreesia ach ...

A downtrend has been apparent in Phreesia (PHR) lately with too much selling pressure. The stock has declined 32.2% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This ...

The company's third-quarter performance wasn't nearly as bad as the investor reaction to it might suggest.The stock of healthcare provider services specialist Phreesia (PHR 23.31%) wasn't looking all that healthy on Tuesday. Investors were clearly displeased with the company's latest quarterly earnings release, and they expressed this sentiment by selling their stock. It fell by more than 23% that trading session. Double-digit improvementsPhreesia published its third quarter of fiscal 2026 figures after mar ...

Financial Performance - Total revenue increased 13% to $120.3 million for the three months ended October 31, 2025, compared to $106.8 million for the same period in 2024[163]. - Net income was $4.3 million for the three months ended October 31, 2025, compared to a net loss of $14.4 million for the same period in 2024[163]. - Adjusted EBITDA was $29.1 million for the three months ended October 31, 2025, compared to $9.8 million for the same period in 2024[163]. - Free cash flow was $8.8 million for the three months ended October 31, 2025, compared to $1.6 million for the same period in 2024[163]. - Total revenue for the nine months ended October 31, 2025, was $353.5 million, a 14% increase from $310.1 million for the same period in 2024[195]. - Adjusted EBITDA for the three months ended October 31, 2025, was $29.1 million, up 198% from $9.8 million in the same period of 2024[231]. - Net cash provided by operating activities for the nine months ended October 31, 2025, was $45.2 million, significantly higher than $16.1 million for the same period in 2024[246]. Revenue Breakdown - Subscription and related services revenue increased by $6.1 million to $55.5 million for the three months ended October 31, 2025, representing a 12% growth year-over-year[194]. - Payment processing fees revenue rose by $2.7 million to $27.4 million for the three months ended October 31, 2025, an 11% increase compared to the prior year[196]. - Network solutions revenue increased by $4.7 million to $37.4 million for the three months ended October 31, 2025, reflecting a 14% growth year-over-year[196]. - Subscription and related services revenue for the nine months ended October 31, 2025, increased by $18.8 million to $163.5 million, a 13% growth year-over-year[197]. - Payment processing fees revenue for the nine months ended October 31, 2025, rose by $8.7 million to $85.7 million, an 11% increase compared to the prior year[197]. - Network solutions revenue for the nine months ended October 31, 2025, increased by $15.9 million to $104.2 million, reflecting an 18% growth year-over-year[197]. Expenses - Cost of revenue (excluding depreciation and amortization) for the three months ended October 31, 2025, was $18.3 million, a 3% increase from $17.9 million in the same period of 2024[198]. - Payment processing expense for the three months ended October 31, 2025, increased by $3.0 million to $19.7 million, an 18% rise compared to $16.7 million in the prior year[202]. - Sales and marketing expense decreased by $5.9 million to $24.1 million for the three months ended October 31, 2025, a 20% decline compared to $30.1 million for the same period in 2024[204]. - Research and development expense increased by $0.1 million to $29.5 million for the three months ended October 31, 2025, remaining relatively stable with a 0% change from $29.3 million in 2024[208]. - General and administrative expense decreased by $2.1 million to $17.5 million for the three months ended October 31, 2025, an 11% decline compared to $19.6 million for the same period in 2024[212]. - Sales and marketing expense decreased by $16.7 million to $75.6 million for the nine months ended October 31, 2025, an 18% decline compared to $92.3 million in 2024[206]. - Research and development expense increased by $2.8 million to $90.6 million for the nine months ended October 31, 2025, a 3% increase from $87.7 million in 2024[210]. - General and administrative expense decreased by $5.2 million to $52.9 million for the nine months ended October 31, 2025, a 9% decline compared to $58.2 million in 2024[214]. - Amortization expense increased by $2.2 million to $12.3 million for the nine months ended October 31, 2025, a 22% increase from $10.1 million in 2024[219]. Cash and Financing - Cash and cash equivalents as of October 31, 2025, were $106.4 million, an increase of $22.2 million compared to January 31, 2025[163]. - The AccessOne Acquisition was completed on November 12, 2025, for a total cash consideration of $160 million, funded by cash and a $110 million secured term loan[236]. - The Bridge Loan associated with the AccessOne Acquisition has an outstanding principal of $110 million and matures on November 11, 2026, with an interest rate that increases by 0.5% every three months[237]. - The company entered into a 364-day secured term loan of $110 million on November 12, 2025, with an interest rate of three-month SOFR plus a margin of 4.00% per annum, increasing by 0.5% every three months[266]. - The Capital One Credit Facility, entered in December 2023, provides a $50 million revolving credit line, enhancing financial flexibility through fiscal 2028[238]. - The company expects that its cash and cash equivalents, along with cash generated from operations, will be sufficient to meet its needs for at least the next 12 months[242]. - As of October 31, 2025, the company had cash and cash equivalents primarily in money market funds and cash deposits, with a portfolio relatively insensitive to interest rate changes[264]. Foreign Currency and Market Risk - For the fiscal year ended January 31, 2025, changes in foreign currency exchange rates negatively affected expenses and largely offset operating income[267]. - Approximately 86% of the company's expenses for the three months ended October 31, 2025, were denominated in US Dollars[267]. - Foreign currency gains and losses for the nine months ended October 31, 2025, were gains of $0.2 million and losses of $0.3 million for the same period in 2024[268]. - The company entered into foreign currency forward contracts to hedge a portion of Canadian Dollar payroll payments, with 90% designated as cash flow hedges[269]. - A 1% increase or decrease in foreign exchange rates between the Canadian Dollar, Indian Rupee, and US Dollar is not expected to have a material effect on the company's results of operations or financial condition[270]. - There were no significant changes in the company's market risk disclosures during the nine months ended October 31, 2025[271].

Core Insights - Phreesia, Inc. is a healthcare technology company focused on patient intake management, enhancing operational efficiency and patient engagement [1] - The company has a market capitalization of approximately $1.21 billion and has experienced significant stock price fluctuations over the past year [4] Financial Performance - Phreesia reported solid earnings with two consecutive quarters nearing breakeven, indicating progress towards profitability [3][5] - Despite the positive earnings report, the stock price declined by approximately 0.86%, fluctuating between $19.40 and $21.24 [2][5] Market Outlook - Canaccord Genuity set a price target of $33 for Phreesia, suggesting a potential increase of about 64% from its trading price of $20.12 [2][5] - The stock has seen a high of $32.76 and a low of $18.55 over the past year, reflecting volatility in the market [4]

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 50 points on Tuesday.The Dow traded up 0.22% to 47,845.80 while the NASDAQ rose 0.22% to 23,597.71. The S&P 500 also rose, gaining, 0.23% to 6,862.11.Check This Out: How To Earn $500 A Month From Cracker Barrel Stock Ahead Of Q1 EarningsLeading and Lagging SectorsEnergy shares jumped by 1.5% on Tuesday.In trading on Tuesday, health care stocks fell by 0.4%.Top HeadlineAutoZone, Inc. (NYSE:AZO) stock fell around 7% on ...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 50 points on Tuesday.The Dow traded up 0.22% to 47,845.80 while the NASDAQ rose 0.22% to 23,597.71. The S&P 500 also rose, gaining, 0.23% to 6,862.11.Check This Out: How To Earn $500 A Month From Cracker Barrel Stock Ahead Of Q1 EarningsLeading and Lagging SectorsEnergy shares jumped by 1.5% on Tuesday.In trading on Tuesday, health care stocks fell by 0.4%.Top HeadlineAutoZone, Inc. (NYSE:AZO) stock fell around 7% on ...

Group 1 - The core focus is on Phreesia's potential acceleration towards profitability following two consecutive quarters that were nearly breakeven [1]

Core Insights - Phreesia Inc. is a healthcare technology company focused on patient intake management solutions, aiming to enhance efficiency and patient experience in a competitive landscape [1] Financial Performance - On December 8, 2025, Phreesia reported earnings per share (EPS) of $0.07, which was below the estimated $0.24, indicating profitability challenges [2][6] - The company generated revenue of approximately $120.3 million, missing the estimated $132.5 million, suggesting difficulties in achieving sales targets [3][6] - Analysts had anticipated earnings of 2 cents per share on revenue of $120.05 million, indicating that actual revenue was slightly above these expectations but still below broader market estimates [3] Financial Ratios - The price-to-sales ratio is about 2.60, suggesting investors are willing to pay $2.60 for every dollar of sales [4] - The enterprise value to sales ratio is approximately 2.38, indicating the company's valuation relative to its revenue [4] - Phreesia has a low debt-to-equity ratio of about 0.01, suggesting minimal reliance on debt financing [5] - The current ratio of approximately 2.44 indicates a strong ability to cover short-term liabilities with short-term assets, reflecting solid liquidity [5]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...